Feb22 event *remove after event end

Gain Therapeutics' 2024 R&D update with KOL and Analyst Insight

Register Here >>

subpage banner

science(overview)

Science

Discovering and developing the next generation of allosteric small molecule therapies

Allosteric binding occurs when a molecule binds to a protein at a site other than the enzyme’s active site where the enzyme typically performs its function. The term comes from the Greek word for other site”. This allosteric interaction leads to a conformational change of the protein, which changes the protein's affinity for a substrate.

moleculeTherapies

Traditional drugs bind to the Active Site

  • Competition with natural substrate can limit efficacy
  • More off-target effects as sites are highly conserved across many proteins

 

Gain’s drugs target Allosteric Sites

  • Non-competitive with natural substrate
  • Highly specific and better drug properties
  • Expands target universe

Allostery offers a degree of control that is unattainable when targeting the active site, allowing researchers to fine-tune how a drug will alter the activity level of a specific protein in a specific disease. Gain’s allosteric modulators are disease-agnostic and designed to modulate a protein to restore or disrupt function as needed via stabilization, destabilization, degradation, inhibition or activation.